Literature DB >> 2439572

The mode of action of interferons in viral infections and their possible role in the control of hepatitis B.

A Billiau.   

Abstract

Interferons can alter the course of virus infections by inhibiting virus replication at the intracellular level and by modifying the aspecific and specific immune response to viral antigens in body fluids and on cellular surfaces. Treatment of isolated cells with interferon renders them resistant to infections by viruses belonging to virtually any family. Knowledge of the mechanism of this effect is derived from studies employing both DNA (especially vaccinia virus and SV40) and RNA-viruses (especially picorna-, toga-, rhabdo-, reo- and retroviruses). Interferon induces multiple alterations in the level and state of intracellular regulatory molecules, leading to inhibition of virus replication at several possible steps. In the case of certain DNA viruses, transcription of viral DNA seems to be inhibited. In the case of RNA viruses the target for interferon action is mainly translation. The retroviridae constitute a special case and, in view of their analogy with the hepadnaviridae, are of particular relevance to the possible effects of interferon on the replication of HBV. Interferon inhibits one or more initial stages of primary infection of cells by transforming or nontransforming retroviruses, thereby preventing or delaying the synthesis and/or integration of viral DNA. In cells that already contain an integrated and fully expressed retrovirus genome, interferon treatment results in a reduced release of viral particles as well as a downward shift of the ratios between the numbers of infectious vs noninfectious particles. Immuno-modulatory properties of interferon which might alter the course of HBV-infection include: potentiation of cytotoxic activity of lymphocytes and macrophages; direct anti-inflammatory effects; enhancement or depression in antibody formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2439572     DOI: 10.1016/s0168-8278(86)80117-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  5 in total

1.  Clinical study on the treatment of liver fibrosis due to hepatitis B by IFN-alpha(1) and traditional medicine preparation.

Authors:  Ming-Liang Cheng; Ya-Yun Wu; Ke-Fu Huang; Tian-Yong Luo; Yi-Shen Ding; Yin-Yin Lu; Ren-Cai Liu; Jun Wu
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

2.  Antiviral treatment with alpha interferon up-regulates CD14 on liver macrophages and its soluble form in patients with chronic hepatitis B.

Authors:  Patrizia Carotenuto; Debby van Riel; André Artsen; Sven Bruijns; Fons G Uytdehaag; Jon D Laman; Andeltje B van Nunen; Pieter E Zondervan; Robert A De Man; Albert D Osterhaus; Oscar Pontesilli
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 3.  Invasive and non-invasive diagnosis of cirrhosis and portal hypertension.

Authors:  Moon Young Kim; Woo Kyoung Jeong; Soon Koo Baik
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 4.  Interferon in the management of chronic hepatitis B.

Authors:  R P Perrillo
Journal:  Dig Dis Sci       Date:  1993-04       Impact factor: 3.199

5.  Regulation of T cell function by microRNA-720.

Authors:  Yu Wang; Zheng Zhang; Dong Ji; Guo-Feng Chen; Xia Feng; Lu-Lu Gong; Jian Guo; Zhi-Wei Li; Cai-Feng Chen; Bin-Bin Zhao; Zhi-Guo Li; Qi-Jing Li; Hui-Ping Yan; Gregory Sempowski; Fu-Sheng Wang; You-Wen He
Journal:  Sci Rep       Date:  2015-07-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.